



INSTITUTE OF
HEALTH ECONOMICS
ALBERTA CANADA

Institute of Health Economics Inaugural Methodology Forum:

Prioritizing Methodological Research in Evaluation of Health Technologies



**September 23 - 24, 2010
Edmonton, Alberta, Canada
The Westin Edmonton**

**Chair: Michael Drummond, University of York (UK)
Program Development Leads: Deborah Marshall, University of Calgary (Can) &
Michael Drummond, University of York (UK).**



INSTITUTE OF
HEALTH ECONOMICS
ALBERTA CANADA

September 23, 2010

Dear Forum Attendee:

On behalf of the Institute of Health Economics (IHE), I welcome you to the Inaugural IHE Methodology Forum: *Prioritizing Methodological Research in Evaluation of Health Technologies* sponsored and supported by the Institute of Health Economics, Canadian Agency for Drugs and Technologies in Health, National Institute for Clinical Excellence, and IHE Board member organizations: Merck, Pfizer, Eli Lilly, Astra Zeneca, GlaxoSmithKline and Alberta Health and Wellness. I hope you will find the Forum to be stimulating and productive.

Attendees from academia, government, industry and stakeholders involved in the production and use of evidence, have been brought together to discuss methodological challenges in evaluation of technologies and to identify priorities for research methods development. We all need to work together to make sure that valuable and beneficial health technologies are made accessible to Canadians. To do that, we must continually evolve the methods and tools we use to assess such technologies, incorporating the latest knowledge and research.

I would like to thank Dr. Egon Jonsson and the team at the IHE, as well as all the IHE Board members for their ongoing work in developing partnerships which can support the development of evidence-based policy and practice in our health system. I would like to express special thanks to Forum Chair, Dr. Michael Drummond from York University and to Dr. Deborah Marshall from the University of Calgary for leading development of this program.

I hope you will enjoy this inaugural methodology forum and trust it will be the start of an ongoing dialogue. Thank you for coming.

Sincerely,

Dr. Lorne Tyrrell
Chair, Institute of Health Economics
GSK/CIHR in Virology, University of Alberta

The Institute of Health Economics

The Institute of Health Economics (IHE) is a non-profit Alberta-based organization committed to producing, gathering, and disseminating health research findings from health economics, health policy, health technology assessment and comparative effectiveness research to improve the delivery of health care and health outcomes.

Institute of Health Economics Board Members

Chair and CEO

Lorne Tyrrell, Chair, Institute of Health Economics and Professor and CIHR/GSK Chair in Virology, University of Alberta

Egon Jonsson, Executive Director and CEO, Institute of Health Economics, Professor, University of Alberta, University of Calgary

Government and Public Authorities

Jay Ramotar, Deputy Minister, Alberta Health and Wellness

Annette Trimbee, Deputy Minister, Advanced Education and Technology

Jacques Magnan, Interim President and CEO, Alberta Innovates - Health Solutions

Alison Tonge, Executive Vice-President, Strategy & Performance, Alberta Health Services

Academia

Renee Elio, Associate Vice-President Research, University of Alberta

Tom Feasby, Dean, Faculty of Medicine, University of Calgary

Philip Baker, Dean, Faculty of Medicine and Dentistry, University of Alberta

Tom Noseworthy, Professor and Head, Community Health Sciences, University of Calgary

James Kehrer, Dean, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta

Herb Emery, Professor, Department of Economics, University of Calgary

Doug West, Chair, Department of Economics, University of Alberta

Industry

Terry McCool, Vice President, Corporate Affairs, Eli Lilly Canada Inc.

Patricia Massetti, Vice President Public Affairs and Patient Access, Merck Canada

Bernard Prigent, Vice President & Medical Director, Pfizer Canada Inc.

Grant Perry, Vice President Public Affairs and Reimbursement, GlaxoSmithKline Inc.

William Charnetski, Vice President, Corporate Affairs and General Counsel, AstraZeneca Canada Inc.

Other

Doug Gilpin, Chair, Audit and Finance Committee

Board Secretary

John Sproule, Senior Policy Director, Institute of Health Economics

Board Treasurer

Allison Hagen, Director of Finance, Institute of Health Economics

Methodology Forum Project Team:

Forum Chair: **Michael Drummond**, Professor of Health Economics, University of York

Project Leader: **Deborah Marshall**, Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary

Anderson Chuck, Manager, Decision Analytic Modelling Unit, Institute of Health Economics

John Sproule, Senior Policy Director, Institute of Health Economics

Caitlin Higgins, Forum Secretariat, Buksa Strategic Conference Services

Thanks to all the speakers and panel members who participated in early discussions to support planning for the forum and identification of methodological issues:

Sir Michael Rawlins, National Institute of Clinical Excellence, UK

Egon Jonsson, Institute of Health Economics

Peter Littlejohns, National Institute of Clinical Excellence, UK

Don Husereau, Canadian Agency for Drugs and Technologies on Health

Peter Chinneck, Canadian Agency for Drugs and Technologies on Health

Murray Krahn, University Health Network, Toronto

Mark Sculpher, University of York, UK

Deborah Marshall, University of Calgary

Jeffrey Hoch, University of Toronto

Stirling Bryan, University of British Columbia, Vancouver Health Research Institute

Frédéric Lavoie, Pfizer Canada

Patricia Bayne, Eli Lilly Canada

Rick Fife, Merck Canada

Farzad Ali, Pfizer Canada

Anderson Chuck, Institute of Health Economics

The IHE Methodology Forum is sponsored by the Institute of Health Economics, Canadian Agency for Drugs and Technologies in Health, National Institute for Clinical Excellence, and IHE Board member organizations: Merck Canada, Pfizer Inc., Eli Lilly Canada Inc., Astra Zeneca Canada Inc., GlaxoSmithKline Inc. and Alberta Health and Wellness.

For more information

Forum Secretariat

BUKSA Strategic Conference Services

307, 10328 81 Avenue NW

Edmonton, AB T6E 1X2

Phone: 780.436.0983 ext 231

Fax: 780.437.5984

Email: forum@buksa.com

www.ihe.ca/research/ihe-inaugural-methodology-forum-1/

Forum Agenda

**All meetings to take place in the Devonian Room unless otherwise noted.*

Thursday, September 23, 2010

1430 – 1745	Registration	<i>Foyer</i>
1500 – 1515	Welcome and opening remarks Susan Williams, Assistant Deputy Minister, Alberta Health and Wellness	
1515 – 1530	Overview of the Methodology Forum: <i>Prioritizing methodological research in evaluation of health technologies</i> Michael Drummond, University of York	
1530 – 1600	Identifying NICE’s methodological research priorities: A survey of priorities Mark Sculpher, University of York	
1600 – 1610	International and stakeholder perspectives Chris Henshall, Health Technology Assessment International Policy Forum	
1610 – 1630	Discussion	
1630 – 1645	Refreshment break	<i>Foyer</i>
1645 – 1745	Health policy panel session <i>Moderator: Michael Drummond, University of York</i> <ul style="list-style-type: none">• Brian O’Rourke, Canadian Agency for Drugs and Technology in Health• Robert Peterson, Canadian Institutes of Health Research• Jean Pruneau, Health Canada• Newell McElwee, Merck & Company Inc.	
1745 – 1830	Reception	<i>Strathcona Room</i>
1830 – 2030	Dinner	<i>Strathcona Room</i>

Forum Agenda Continued...

**All meetings to take place in the Devonian Room unless otherwise noted.*

Friday, September 24, 2010

0700 – 1530	Registration	<i>Foyer</i>
0700 – 0800	Continental breakfast	<i>Strathcona Room</i>
0800 – 0815	Overview of the agenda Michael Drummond, University of York	
0815 – 0900	Methodological challenge #1 – Data quality and the development of national costing panels to better utilize administrative data <i>Session chair and discussant: Tammy Clifford, Canadian Agency for Drugs and Technologies in Health</i> <ul style="list-style-type: none">• Larry Svenson, Alberta Health and Wellness• Philip Jacobs, University of Alberta; Institute of Health Economics	
0900 – 0930	Methodological challenge #2 – Incorporating routine measurement of patient-reported outcomes <i>Session chair and discussant: Herb Emery, University of Calgary</i> <ul style="list-style-type: none">• Stirling Bryan, University of British Columbia; Vancouver Coastal Health Research Institute	
0930 – 1000	Refreshment break	<i>Foyer</i>
1000 – 1045	Methodological challenge #3 – How to incorporate multi-criteria decision frameworks into economic evaluations and decision making <i>Session chair and discussant: Farzad Ali, Pfizer Canada Inc.</i> <ul style="list-style-type: none">• Stuart Peacock, British Columbia Cancer Agency; University of British Columbia• Deborah Marshall, University of Calgary	

Forum Agenda Continued...

**All meetings to take place in the Devonian Room unless otherwise noted.*

1045 – 1115	Methodological challenge #4 – Approaches to mitigating against methodologic bias in economic evaluations <i>Session chair and discussant: Karen Lee, Canadian Agency for Drugs and Technologies in Health</i> <ul style="list-style-type: none">• Braden Manns, University of Calgary	
1115 – 1230	Lunch	<i>Strathcona Room</i>
1230 – 1330	Methodological challenge #5 – How to incorporate a broader health system and societal perspective in evaluation including the value of innovation <i>Session chair and discussant: Mark Sculpher, University of York</i> <ul style="list-style-type: none">• Marc Berger, Eli Lilly and Company• Don Husereau, Canadian Agency for Drugs and Technologies in Health	
1330 – 1445	Prioritization panel discussion and debate <i>Moderator: Michael Drummond, University of York</i> <ul style="list-style-type: none">• Tom Noseworthy, University of Calgary• Kathy Kovacs Burns, University of Alberta• Terri Jackson, University of Alberta• Nigel Rawson, GlaxoSmithKline Inc.	
1445 – 1500	Refreshment break	<i>Foyer</i>
1500 – 1515	Closing comments and next steps Michael Drummond, University of York	

Forum Moderator



Michael Drummond, Professor of Health Economics, University of York

Dr. Michael Drummond is Professor of Health Economics and former Director of the Centre for Health Economics at the University of York. His particular field of interest is in the economic evaluation of health care treatments and programmes. He has undertaken evaluations in a wide range of medical fields including care of the elderly, neonatal intensive care, immunization programmes, services for people with AIDS, eye health care and pharmaceuticals.

Dr. Drummond is the author of two major textbooks and more than 550 scientific papers, has acted as a consultant to the World Health Organization, and was Project Leader of a European Union Project on the Methodology of Economic Appraisal of Health Technology. He was President of the International Society of Technology Assessment in Health Care, and the International Society for Pharmacoeconomics and Outcomes Research.

Currently, Dr. Drummond is a member of the Guidelines Review Panels of the National Institute for Health and Clinical Excellence (NICE) in the UK, and is a Principal Consultant for i3Innovus. In 2008 he received an Honorary Doctor of Science from City University, London.

Forum Speakers



Marc Berger, Vice President, Global Health Outcomes, Eli Lilly and Company

Dr. Marc L. Berger is Vice President, Global Health Outcomes at Eli Lilly and Company. He joined Eli Lilly in April 2007 after retiring from Merck & Co., Inc. where he held the position of Vice President, Outcomes Research and Management. He holds a medical degree from Johns Hopkins University School of Medicine and has held adjunct appointments as Senior Fellow at the Leonard Davis Institute at the Wharton School of the University of Pennsylvania and Professor in the Department of Health Policy and Administration at the University of North Carolina at Chapel Hill School of Public Health.

Dr. Berger has served on the Medicare Evidence Development & Coverage Advisory Committee (MedCAC) for the Center for Medicare & Medicaid Services (CMS), the board of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and the steering committee for the Agency for Health Care Research and Quality (AHRQ) Centers for Research and Education on Therapeutics (CERTs). He has published widely in peer-reviewed journals in health services research, outcomes research, health economics, and health policy.



Stirling Bryan, Professor, Department of Medicine, University of British Columbia; Director, Centre for Clinical Epidemiology & Evaluation, Vancouver Coastal Health Research Institute

Dr. Stirling Bryan is Director of the Centre for Clinical Epidemiology & Evaluation, and full professor in the School of Population & Public Health at the University of British Columbia (UBC). He is also honorary professor at the University of Birmingham (UK), an Associate of the UBC Centre for Health Services & Policy Research and an Adjunct Associate at the Center for Health Policy at Stanford University.

In 2005 and 2006, Dr. Bryan was a Commonwealth Fund Harkness Fellow in Health Care Policy, based at Stanford University. He sits on the UK Medical Research Council's College of Experts, the Scientific Committee of the International Health Economics Association and the

Forum Speakers Continued...

Editorial Board of Health Economics, a journal for which he is also an Associate Editor. Dr. Bryan's research interests span the areas of economic evaluation and health technology assessment from applied and methodological perspectives, including preference elicitation and outcome measurement, and the use of economic analyses in decision-making.



Chris Henshall, Chair, HTAi Policy Forum, Health Technology Assessment International

Dr. Chris Henshall is an independent consultant, advising governments, public and private sector organisations on health, research and innovation policy. He was the founding President of Health Technology Assessment International (HTAi) and is currently Chair of the HTAi Policy Forum and a board member of the Alberta Research and Innovation Authority, as well as an Associate Professor in the Health Economics Research Group at Brunel University, and an honorary Fellow in the Centre for Health Economics at the University of York.

Dr. Henshall has worked previously for the Health Promotion Research Trust, the UK Medical Research Council, the Department of Health and National Health Service (NHS) in England where he was involved in: establishing the NHS research and development budget; the NHS Health Technology Assessment Programme and the National Institute for Health and Clinical Excellence; the Department of Trade and Industry where he was responsible for UK science and innovation policy and funding; and the University of York where he was responsible for promoting enterprise and innovation and links with the economy, government and businesses at home and overseas.



Don Husereau, Senior Advisor, Canadian Agency for Drugs and Technologies in Health

Mr. Don Husereau is a Senior Advisor for the Canadian Agency for Drugs and Technologies in Health (CADTH). He received both his Bachelor's of Science degree in Pharmacy in 1993 and his Master's of Science in 2000 from the University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences, where he also served as a lecturer and course facilitator.

He joined CADTH in 2001 and, since then, has contributed to the development of several programs including an environmental scanning program, and a rapid review service. At CADTH Mr. Husereau developed the Health Technology Analysis Exchange, a network of Canadian Health Technology Assessment producers, who coordinate the gathering of evidence and policy advice regarding health technologies to support the needs of the Canadian federal, provincial, and territorial health jurisdictions. He has also developed CADTH's coordinated national process for identification, refinement, prioritization, and assignment of policy research. In 2005, he led the completion of the 3rd edition of the CADTH Health Technology Assessment (HTA) Guidelines for the Economic Evaluation of Health Technologies: Canada.

He is an editorial advisor for Value in Health and an academic editor for the Public Library of Science ONE journal, as well as a reviewer for the Cochrane Hypertension Review Group and Mediadoctor.ca. Mr. Husereau's interests include the disciplines of scientific epistemology and judgment and decision-making and their application to health economics and policy decisions.

Forum Speakers Continued...



Dr. Terri Jackson, Associate Professor, Division of Pulmonary Medicine, Faculty of Medicine and Dentistry, University of Alberta

Dr. Terri Jackson is Associate Professor in the Division of Pulmonary Medicine in the University of Alberta Faculty of Medicine and Dentistry. Prior to this time, Dr. Jackson was on the faculty of the Australian Centre for Economic Research on Health at the University of Queensland. She served for 10 years as a health economist on the Australian Medical Services Advisory Committee (MSAC), until 2008.

Her major research interests focus on issues of technical efficiency in the provision of hospital-based care and in funding systems which make use of casemix adjustment. She has recently completed a set of studies on the economics of patient safety in hospital care for the Australian Commission on Safety and Quality in Health Care.



Dr. Philip Jacobs, Professor, Faculty of Medicine and Dentistry, University of Alberta; Director of Collaborations, Institute of Health Economics

Dr. Philip Jacobs is a professor of health economics in the Department of Medicine at the University of Alberta, and an economist at the Institute of Health Economics. He received his PhD in economics from the University of York and is a Certified Management Accountant. He is the author of the textbook, *The Economics of Health and Medical Care*. His research has been in the area of costing of health services, and he was director of a project to develop a manual of standard costs for the provinces. His recent research is in the area of the economics of vaccines and the introduction of economics in public health decision making.



Dr. Kathy Kovacs Burns, Associate Director, Health Sciences Council, University of Alberta

Dr. Kathy Kovacs Burns' academic, research and volunteer interests include public, patient and stakeholder engagement in health and social care decisions and policies. This applies to patient safety and quality of life related to team-based health care delivery and practices, and particularly to effective evidence-based interventions, including health technology assessment and post-market health product safety.

As Associate Director, Health Sciences Council, University of Alberta, she coordinates interdisciplinary and interprofessional health science research, education and practices, including with government, community and health partners. Her work and research link closely with community organizations and committee work, which includes health charities governments and institutions, and other organizations at the provincial, national and international levels.

She does research, publishes, and presents at special events, meetings and national and international conferences, as well as provides consultations on her research and volunteer initiatives.



Dr. Braden Manns, Associate Professor, Faculty of Medicine, University of Calgary

Dr. Braden Manns is an Associate Professor at the University of Calgary in the Departments of Medicine and Community Health Sciences and an Alberta Innovates – Health Solutions Health Scholar. He has expertise in Applied Health Economics, with a track record of producing research that impacts Canadian and international health policy. He also has experience in pharmaceutical priority setting, having served on provincial (2002 - 2006) and national (2003 - 2008) committees for drug evaluation, including a term as Chair of Canadian Expert Drug Advisory Committee from 2006-2008. Dr. Manns continues to chair the Canadian

Forum Speakers Continued...

Society of Nephrology Scientific Committee and maintains strong links with researchers across Canada. In addition to these roles and skills, Dr. Manns teaches a graduate course in economic evaluation and supervises graduate students at all levels of training.



Dr. Deborah Marshall, Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary; Canada Research Chair, Health Services and Systems Research; Director, Health Technology Assessment, Alberta Bone and Joint Health Institute

Dr. Deborah Marshall is an Associate Professor in the Department of Community Health Sciences, University of Calgary and the Director of Health Technology Assessment (HTA) at the Alberta Bone and Joint Health Institute. She is also Canada Research Chair for Health Services and Systems Research which is a Health Technology Assessment (HTA) research programme involving synthesis of evidence, measurement of preferences, cost-effectiveness analysis, and decision modeling of health systems. Dr. Marshall has research experience in HTA agencies, academic institutions and industry settings in Canada, US and Europe.

Her key projects, funded through the former Alberta Heritage Foundation for Medical Research, Canadian Institutes for Health Research and the Canadian Arthritis Society, focus on understanding patient expectations and preferences for joint replacement surgery and the development of a system dynamics model to inform decisions about health-care service delivery for patients with hip and knee osteoarthritis. Her peer-reviewed grants from the US National Cancer Institute (NCI) and the Ontario Institute for Cancer Research involve measuring preferences for personalized medicine using conjoint analysis and cost-effectiveness modeling in breast cancer.

Dr. Marshall is an active member of the International Society for Pharmacoeconomics and Outcomes Research as a member of the Patient Preferences Special Interest Group. She was also a member of the CADTH/NCIC Working Group to develop cancer-specific economic evaluation guidelines, and the NCI Clinical Trials and Translational Research Advisory Board Cost-Effectiveness Analysis Working Group. She also serves on the editorial board of the *International Journal for Technology Assessment in Health Care*.



Dr. Newell McElwee, Executive Director, U.S. Outcomes Research Group, Merck & Company Inc.

Dr. Newell McElwee is pharmacist and epidemiologist with over 20 years of experience in outcomes research. For the past 12 years, he has led groups of scientists in the pharmaceutical industry working in outcomes research, evidence based medicine, health technology assessment, comparative effectiveness, quality measurement and improvement, health disparities, and payment policy.

Dr. McElwee is currently the Executive Director of the U.S. Outcomes Research group at Merck & Company Inc. where he leads a group of scientists who are primarily focused in the areas of quality measurement and improvement, medication adherence, health technology assessment, and health care reform.

Dr. McElwee has been a member of the Agency for Healthcare Research and Quality (AHRQ) Effective Health Care Stakeholder Group, and AHRQ study sections, and he is currently on the Steering Committee for the AHRQ Centers for Education, Research, and Training. He is on the Advisory Board for Institute for Clinical and Economic Review at Harvard Medical School, the

Forum Speakers Continued...

Advisory Board for the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, the Dean's Advisory Council at the University of Washington School of Pharmacy, the Executive Committee for the Foundation for Managed Care Pharmacy, and is a member of the Institute of Medicine's Roundtable on Health Disparities.

Dr. McElwee received his B.S. in Pharmacy from Northeast Louisiana University, his PharmD degree at Mercer University, and his MSPH (epidemiology) at the University of Utah. He also completed an ASHP residency in clinical pharmacy and a research fellowship in clinical pharmacology and toxicology.



Dr. Tom Noseworthy, Professor, Department of Community Sciences, University of Calgary

Dr. Tom Noseworthy is a Professor of Health Policy and Management in the Department of Community Health Sciences, University of Calgary. He is the former Vice President, Medical Services; CEO of the Royal Alexandra Hospitals; and Chair of the Department of Public Health Sciences, Faculty of Medicine and Dentistry, University of Alberta. He holds a Master of Science in Experimental Medicine from the University of Alberta, and a Master of Public Health – Health Policy and Management from Harvard University.

Dr. Noseworthy is a physician with specialty certification in the Royal College of Physicians and Surgeons of Canada, and the American Colleges of Physicians, American College of Chest Physicians, and American College of Critical Care Medicine. He served as a member of the Prime Minister's National Forum on Health from 1994-1997, and chaired the Steering Committee; co-chaired the Advisory Council on Health Infostructure (Federal Health Minister) from 1997-1999; chaired the Senior Reference Committee for Alberta Wellnet from 1997-2002; was Chair of the Western Canada Waiting List Project from 1999-2006, and now chairs the research collaboration known as the Western Canada Waiting List Investigators. He was a founding Director of Canadian Doctors for Medicare in 2007.

In 2005, Dr. Noseworthy was awarded the Alberta Centennial Medal by the Province of Alberta for contributions to health care and policy and was named as one of Alberta's top 100 Physicians of the Century by the Alberta Medical Association and College of Physicians and Surgeons of Alberta.

In 2007, Dr. Noseworthy was named by the Governor General as a Member of the Order of Canada for contributions to health policy and Medicare.



Dr. Brian O'Rourke, President and Chief Executive Officer, Canadian Agency for Drugs and Technologies in Health

Dr. Brian O'Rourke is the President and Chief Executive Officer of the Canadian Agency for Drugs and Technologies in Health (CADTH). He joined CADTH in January 2009 as the Vice-President of the Common Drug Review following a distinguished career as a Pharmacist and Health Services Operations Officer with the Canadian Forces (CF). As a military Pharmacist Officer, Dr. O'Rourke held positions in Canada and abroad, as a Clinical Pharmacist, Director of Pharmacy, Pharmacy Policy and Standards Officer, and as the Director of Pharmaceutical and Medical Supplies for the Canadian Forces.

In 1997, following an operational deployment as the NATO Chief of Medical Plans and Operations in the former Yugoslavia, Dr. O'Rourke was appointed as the Director of Medical Logistics for the CF. He also served as the Director of Health Services Delivery for the CF, the

Forum Speakers Continued...

Special Assistant to the Chief of Military Personnel at National Defence Headquarters, and as the Deputy Commander of the Canadian Forces Health Services Group.

Dr. O'Rourke holds a Bachelor of Science in Pharmacy degree from Dalhousie University and a Doctor of Pharmacy degree from the University of Toronto. He is an active member of the Canadian Pharmacists Association, the Canadian Society of Hospital Pharmacists, and the Canadian College of Health Service Executives.

Colonel (Retired) O'Rourke was appointed by the Governor General as an Officer of the Order of Military Merit in 2005. He has also received the Canadian Peace Keeping Service Medal, the NATO Medal for Former Yugoslavia, the Special Service Medal, and he holds the Second Clasp to the Canadian Forces' Decoration.



Dr. Stuart Peacock, Co-Director, Canadian Centre for Applied Research in Cancer Control; Senior Scientist, British Columbia Cancer Agency; Associate Professor, University of British Columbia

Dr. Stuart Peacock is Co-Director of the Canadian Centre for Applied Research in Cancer Control (ARCC). ARCC's mission is to improve cancer control and the delivery of cancer care through interdisciplinary, Pan-Canadian leadership in health economics, services, policy and ethics research, education, and knowledge translation. He is an Associate Professor in the School of Population and Public Health at the University of British Columbia, a Senior Scientist at the British Columbia Cancer Agency, and a Michael Smith Foundation for Health Research Scholar.

Previously, Dr. Peacock held positions at Monash University, Australia, and the University of York, UK. His research interests include priority setting methods, the economics of cancer control, health-related quality of life, and health econometrics. He has published over 130 papers on health economics and co-authored a book titled *Efficiency Measurement in Health and Health Care*. He has acted as a consultant on priority setting methods for over fifty health agencies on four continents, including the World Health Organization.



Dr. Robert Peterson, Executive Director, Drug Safety and Effectiveness Network, Canadian Institutes of Health Research

Dr. Robert Peterson was appointed as Executive Director, Drug Safety and Effectiveness Network (DSEN) in December 2009. DSEN is a network that responds to decision-makers' drug safety and effectiveness information needs and increase capacity within Canada to undertake high-quality research in this area. New evidence generated via the Network will inform decision-making about the regulation, public reimbursement, and safe and optimal prescribing and use of drugs within the Canadian health care system.

Dr. Peterson received a M.D. degree and a Ph.D. in Pharmacology from Yale University in 1974, and completed a Master's of Public Health at Harvard University in 1996.

A member of many international boards and an active researcher, Dr. Peterson has been Director of the Section of Paediatric Clinical Pharmacology at the University of Colorado, Professor of Paediatrics and Pharmacology and Chairman of the Department of Paediatrics at the University of Ottawa Faculty of Medicine, and Director of the Children's Hospital of Eastern Ontario Research Institute.

Forum Speakers Continued...

He has also served as the Director General of the Therapeutic Products Directorate at Health Canada from 2000 to 2005, before becoming Clinical Professor of Paediatrics at the University of British Columbia and Senior Associate Clinician Scientist at the Child and Family Research Institute at BC Children's Hospital. He was appointed to the Canadian Expert Drug Advisory Committee in 2005 and assumed the role of Chair in 2008. He has authored numerous papers and chapters in paediatric clinical pharmacology and toxicology.



Mr. Jean Pruneau, Executive Director, Office of Pharmaceuticals Management Strategies, Strategic Policy Branch, Health Canada

Mr. Jean Pruneau has been employed with Health Canada since 1992. He is a policy generalist who contributed to various policy issues including Information management and information technology planning, tobacco regulations, privacy, electronic health records, rural health, mental health, and family violence. He has been involved in a number of in various roles including working as a Senior Advisor to Deputy Ministers.

He is currently the Acting Executive Director for the Office of Pharmaceutical Management Strategies, Strategic Policy Branch for Health Canada. Mr. Pruneau holds a Bachelor's of Science degree in Computer Science Systems (Artificial Intelligence) and a Masters of Business Administration from Queen's University.



Dr. Nigel Rawson, Pharmacoepidemiologist, GlaxoSmithKline

Dr. Nigel Rawson is a pharmacoepidemiologist at GlaxoSmithKline in Mississauga and an Adjunct Professor at the University of Waterloo. He has worked on epidemiologic studies of the use of drugs and their outcomes, particularly their safety, for most of his career.

In the UK in the 1980s, he was instrumental in the development of Prescription-Event Monitoring, an epidemiologic method to detect acute adverse reactions to new drugs in the general practice setting. He then moved to Canada and was in academia at the University of Saskatchewan and Memorial University of Newfoundland where his research focused on studies of population-based drug use and safety utilizing the Saskatchewan administrative healthcare utilization databases, and the evaluation of issues affecting access to new medications in Canada.

Between 2001 and 2004, Dr. Rawson was a senior researcher at the Center for Health Care Policy and Evaluation in Minneapolis working primarily on drug safety studies in association with the US Food and Drug Administration. Since his return from the US, Dr. Rawson has been at GlaxoSmithKline, where he is responsible for providing epidemiologic advice and analysis for the company's new and currently marketed products.

Dr. Rawson is a founding member of the Canadian Association for Population Therapeutics and was awarded Honorary Lifetime Membership in 1999; he is currently Immediate Past-President of the Association.

Forum Speakers Continued...



Dr. Mark Sculpher, Director, Economic Evaluation and Health Technology Assessment, University of York

Dr. Mark Sculpher is Professor of Health Economics at the Centre for Health Economics, University of York, UK where he is Director of the Programme on Economic Evaluation and Health Technology Assessment. He has worked in the field of economic evaluation and health technology assessment for over 20 years. He has researched in a range of clinical areas including heart disease and various types of cancer. He has also contributed to methods in the field, in particular relating to decision analytic modelling and techniques to handle uncertainty.

Dr. Sculpher has over 170 peer-reviewed publications and is a co-author of two major text books in the area: *Methods for the Economic Evaluation of Health Care Programmes* (OUP, 2005 with Drummond, Torrance, O'Brien and Stoddart) and *Decision Modelling for Health Economic Evaluation* (OUP, 2006 with Briggs and Claxton). He is a member of the UK National Institute of Health Research (NIHR) College of Senior Investigators. He has also been a member of the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee and the NICE Public Health Interventions Advisory Committee. He currently sits on NICE's Diagnostics Advisory Committee. He chaired NICE's 2004 Task Group on methods guidance for economic evaluation and advised the Methods Working Party for the 2008 update of this guidance. Dr. Sculpher also advised health systems internationally on HTA methods including those in Ireland, Portugal and New Zealand.

He has been a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme and currently sits on the UK NIHR/Medical Research Council's Methodology Research Panel. He is President Elect of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).



Mr. Larry Svenson, Senior Manager, Epidemiology and Surveillance, Alberta Health and Wellness

Mr. Larry Svenson is the Senior Manager of Epidemiology and Surveillance with the Surveillance and Assessment Branch of Alberta Health and Wellness. He also is an Adjunct Associate Professor with the School of Public Health at the University of Alberta and the Department of Community Health Sciences at the University of Calgary.

Mr. Svenson was one of the original investigators behind the development of the National Diabetes Surveillance System, the first surveillance system in Canada based on administrative health data. The model has been expanded to include a number of chronic conditions and is now one of the Public Health Agency of Canada's flagship surveillance systems.

He is a member of expert advisory committees to the Public Health Agency of Canada in the areas of neurological conditions, cardiovascular disease, arthritis, chronic respiratory disease, and diabetes. He was also one of four Canadians selected to sit on the North American Free Trade Agreement (NAFTA) Commission for Environmental Cooperation's expert group on asthma surveillance.

Currently, Mr. Svenson is responsible for the development and maintenance of surveillance systems for communicable and non-communicable diseases, mental health, and injury and the use of evidence to inform the development of programs and policies.